HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Matthieu Allez  1     James D. Lewis  2     Timothy Hoops  3     Tony Ma  3     Zhijie Ding  3     Erik Muser  3     Christopher Gasink  3     Remo Panaccione  4     Edward V. Loftus Jr  5     Silvio Danese  6     Bruce E. Sands  7     Peter Irving  8     James Izanec  3    
1 Université de Paris, Paris, France
2 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States
3 Janssen Scientific Affairs, LLC, Horsham, United States
4 University of Calgary, Calgary, Canada
5 Mayo Clinic College of Medicine, Rochester, United States
6 Humanitas Clinical and Research Center, Humanitas University, Milan, Italy
7 Icahn School of Medicine at Mount Sinai, New York, United States
8 Guy’s and Saint Thomas’ Hospitals NHS Trust, London, United Kingdom

Topic
IBD, Immunology

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing